1558 — Yichang Hec Changjiang Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- HK$13.97bn
- HK$14.88bn
- CNY3.72bn
Brief: Yichang Hec Changjiang Pharmaceutical Says Encofosbuvir Tablets (0.3G) Approved For Launch By NMPA
Brief: Yichang HEC Changjiang Pharmaceutical Updates On Filing With Listing Committee
Brief: YiChang HEC Changjiang Pharmaceutical Says Sunshine Lake Pharma To Enter Licensing Agreement
Brief: YiChang HEC Changjiang Pharmaceutical Posts HY Revenue RMB2,454.8 Million
Brief: YiChang HEC ChangJiang Pharmaceutical Posts H1 Net Income RMB684.7 Million
Brief: Yichang Hec Changjiang Pharmaceutical Posts Special Dividend
Brief: Yichang Hec Changjiang Pharmaceutical Says Proposed Privatisation Of Co
Brief: Yichang Hec Changjiang Pharmaceutical Seeks Trading Halt
Brief: Yichang Hec Changjiang Pharmaceutical Posts FY Profit And Total Comprehensive Income Attributable RMB1,992.62 Mln
Brief: Yichang Hec Changjiang Pharmaceutical Sees Net Profit Attributable For Year
Brief: YiChang HEC ChangJiang Pharmaceutical Announces Possible Transfer Of Shares
Brief: Yichang Hec Changjiang Pharmaceutical Seeks Trading Halt
Brief: Yichang Hec Changjiang Pharmaceutical Says Mixed Protamine Human Insulin Injection Approved For Launch From NMPA
Brief: Yichang Hec Changjiang Pharmaceutical Says Chen Hao Appointed Executive Director
Brief: Yichang Hec Changjiang Pharmaceutical Says HY Revenue Rmb3,209.0 Mln
Brief: Yichang HEC Changjiang Pharmaceutical Says Yiqibuvir Tablets Received Notice Of Acceptance
Brief: Yichang Hec Changjiang Pharmaceutical Receives Resignation Letter Tendered By Executive Director
Brief: Yichang Hec Changjiang Pharmaceutical Sees Turnover Of RMB3.2 Billion For Six Months
US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent (updated)